{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:39:19Z","timestamp":1740177559996,"version":"3.37.3"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":120,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.ctarc.2024.100817","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T22:21:34Z","timestamp":1714602094000},"page":"100817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial"],"prefix":"10.1016","volume":"40","author":[{"given":"Dilyara","family":"Kaidarova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edvard","family":"Zhavrid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oxana","family":"Shatkovskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliaksandr","family":"Prokharau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Akhmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dauren","family":"Sembayev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanna","family":"Rutzhanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1885-7494","authenticated-orcid":false,"given":"Alexandr","family":"Ivankov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"28","key":"10.1016\/j.ctarc.2024.100817_bib0001","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2217\/fon-2019-0368","article-title":"Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics","volume":"15","author":"Anderson","year":"2019","journal-title":"Future Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2024.100817_bib0002","first-page":"1117","article-title":"Trastuzumab in breast cancer","volume":"18","author":"Emens","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.ctarc.2024.100817_bib0003","unstructured":"Fagg J. Herceptin biosimilars \u2013 the real prize remains Europe. 2014. Available from: https:\/\/www.evaluate.com\/vantage\/articles\/news\/herceptin-biosimilars-real-prize-remains-europe."},{"issue":"46","key":"10.1016\/j.ctarc.2024.100817_bib0004","doi-asserted-by":"crossref","first-page":"81343","DOI":"10.18632\/oncotarget.18527","article-title":"Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients","volume":"8","author":"Farolfi","year":"2017","journal-title":"Oncotarget"},{"year":"2018","series-title":"Herceptin [package insert]","key":"10.1016\/j.ctarc.2024.100817_bib0005"},{"key":"10.1016\/j.ctarc.2024.100817_bib0006","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.breast.2017.05.004","article-title":"Switching between intravenous and subcutaneous trastuzumab: safety results from the PrefHer trial","volume":"34","author":"Gligorov","year":"2017","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.ctarc.2024.100817_bib0007","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s11523-019-00684-y","article-title":"Subcutaneous Trastuzumab: a review in HER2-positive breast cancer","volume":"14","author":"Heo","year":"2019","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ctarc.2024.100817_bib0008","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14737167.2019.1554437","article-title":"Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries","volume":"19","author":"Inotai","year":"2019","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"9","key":"10.1016\/j.ctarc.2024.100817_bib0009","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicenter, randomized trial","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2024.100817_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.0339","article-title":"Subcutaneous vs Intravenous trastuzumab for patients With ERBB2-positive early breast cancer: final analysis of the HannaH Phase 3 randomized clinical trial","volume":"5","author":"Jackisch","year":"2019","journal-title":"JAMa Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2024.100817_bib0011","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1007\/s12094-017-1684-4","article-title":"Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain","volume":"19","author":"Lopez-Vivanco","year":"2017","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ctarc.2024.100817_bib0012","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.xphs.2016.05.029","article-title":"Subcutaneous injection volume of biopharmaceuticals\u2014pushing the boundaries","volume":"105","author":"Mathaes","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ctarc.2024.100817_bib0013","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.rx.2017.06.003","article-title":"Breast cancer in the 21st century: from early detection to new therapies","volume":"59","author":"Merino Bonilla","year":"2017","journal-title":"Radiologia"},{"key":"10.1016\/j.ctarc.2024.100817_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919887044","article-title":"Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States","volume":"11","author":"Miller","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ctarc.2024.100817_bib0015","series-title":"StatPearls [Internet]","article-title":"Loading Dose. [Updated 2022 Jun 23]","author":"Miniaci","year":"2022"},{"key":"10.1016\/j.ctarc.2024.100817_bib0016","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.breast.2016.07.008","article-title":"Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - an observational study prospectively recording resource utilization in a Swedish healthcare setting","volume":"29","author":"Olofsson","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.ctarc.2024.100817_bib0017","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejca.2017.05.009","article-title":"Patients\u2019 preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: results of the randomized MetaspHer study","volume":"82","author":"Pivot","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2024.100817_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227961","article-title":"Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer","volume":"15","author":"Rojas","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctarc.2024.100817_bib0019","first-page":"51","article-title":"The smooth and bumpy road of trastuzumab administration: from intravenous (IV) in a hospital to subcutaneous (SC) at home. Facts Views Vis","volume":"9","author":"Tjalma","year":"2017","journal-title":"Obgyn"},{"key":"10.1016\/j.ctarc.2024.100817_bib0020","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41416-020-01255-z","article-title":"Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice","volume":"124","author":"Waller","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2024.100817_bib0021","unstructured":"NDDA Available online: http:\/\/register.ndda.kz\/category\/search_prep (accessed on 26 January 2023)."},{"key":"10.1016\/j.ctarc.2024.100817_bib0022","unstructured":"Order of the Minister of Health of the Republic of Kazakhstan dated August 29, 2017 No. 666 On Approval of the List of Medicines and Medical Devices within the Guaranteed Volume of Free Medical Care and in the System of Compulsory Social Health Insurance, Including Certain Categories of Citizens with Certain Diseases. Available online: https:\/\/adilet.zan.kz\/rus\/docs\/V1700015724 (accessed on 26 January 2023)."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294224000297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294224000297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T07:26:12Z","timestamp":1725089172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294224000297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":22,"alternative-id":["S2468294224000297"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100817","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100817"}}